HA
COGT icon

HHLR Advisors’s Cogent Biosciences COGT Stock Holding History

HHLR Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,000,000
Closed -$8.11M – 90
2021
Q2 		$8.11M Hold
1,000,000
– – 0.08% 73
2021
Q1 		$8.78M Hold
1,000,000
– – 0.09% 67
2020
Q4 		$11.2M Buy
+1,000,000
New +$11M 0.09% 70

Other funds holding COGT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

HHLR Advisors's COGT Position: Q3 2021 in Review

HHLR Advisors sold out of Cogent Biosciences (COGT) in Q3 2021, closing a stake of 1,000,000 shares — an estimated $8.11M sold.

HHLR Advisors first reported a position in COGT in Q4 2020 and held it in 3 quarters. The position peaked at $11.2M in Q4 2020. 73 funds tracked by Wall St. Rank hold COGT as of Q3 2021.

  • HHLR Advisors reported no remaining Cogent Biosciences position as of Q3 2021 after selling out during the quarter.
  • HHLR Advisors sold 1,000,000 Cogent Biosciences shares in Q3 2021, an estimated $8.11M.
  • HHLR Advisors first reported a position in Cogent Biosciences in Q4 2020 and held it in 3 quarters.
  • HHLR Advisors's Cogent Biosciences position peaked at $11.2M in Q4 2020.
  • 73 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2021.

Based on HHLR Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.